Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the Safety and efficacy of induction and individualized
neoadjuvant chemotherapy based on oxaliplatin combined with fluorouracil for MRF-negative,
moderate-risk and initially resectable middle and low rectal cancer.